ALT-801
- Generic Name
- ALT-801
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1188450-53-4
- Unique Ingredient Identifier
- QWZ40O5W6K
- Background
ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of ALT-801 in the Treatment of Obesity
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 391
- Registration Number
- NCT05295875
- Locations
- ๐บ๐ธ
Altimmune CTM, Saint George, Utah, United States
๐บ๐ธNational Research Institute, Los Angeles, California, United States
๐บ๐ธCornell University, Joan and Sanford Weill Medical College, New York, New York, United States
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05292911
- Locations
- ๐บ๐ธ
Wake Research CRCN, Las Vegas, Nevada, United States
๐บ๐ธPanax Clinical Research, Miami Lakes, Florida, United States
๐บ๐ธDiagnostics Research Group, San Antonio, Texas, United States
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT05134662
- Locations
- ๐บ๐ธ
Altimmune CTM, Tomball, Texas, United States
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05006885
- Locations
- ๐บ๐ธ
Panax Clinical Research, Miami Lakes, Florida, United States
๐บ๐ธPinnacle Research, San Antonio, Texas, United States
๐บ๐ธDiagnostics Research Group, San Antonio, Texas, United States
ALT-801 DDI Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04972396
- Locations
- ๐ฆ๐บ
Q-Pharm, Herston, Queensland, Australia
๐ฆ๐บCMAX Clinical Research, Adelaide, South Australia, Australia
ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04561245
- Locations
- ๐ฆ๐บ
Nucleus Networks, Herston, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.